Despite the latest reminder of Johnson & Johnson's (JNJ +1%) recall troubles, shares...

Despite the latest reminder of Johnson & Johnson's (JNJ +1%) recall troubles, shares hold gains sparked by Goldman Sachs' upgrade. JNJ “may be on the cusp of an accelerating earnings trajectory, driven by an emerging new product cycle in Pharma, signs of stabilization in Medical devices and diagnostics, and a bottoming out in Consumer," Goldman says.